Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly earnings down, but better than expected

This article was originally published in Scrip

Executive Summary

Having put the bad news out of the way three weeks ago, Lilly presented an unexpectedly rosy picture to investors on January 31 when it released its 2011 results. Fourth quarter adjusted earnings of $969 million were down 22% from the same period in 2010, but that worked out to per share earnings of 87 cents, while various polls of analysts taken before the announcement had expected a figure in the 80 to 81 cent range.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC016114

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel